Evidence map›Paper›PMID 29917000›Full record

ArticleJournal of glaucoma2018

Four Questions for Every Clinician Diagnosing and Monitoring Glaucoma.

Donald C Hood, Carlos G De Moraes

Abstract read
In one paragraph

Article in Journal of glaucoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. A Model of Progression to Help Identify Macular Damage Due to Glaucoma.Investigative ophthalmology & visual science · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Amsler Grid Versus 10-2 Test in Primary Open Angle Glaucoma.Journal of the West African College of Surgeons
    Article
  20. Macular Optical Coherence Tomography Imaging in Glaucoma.Journal of ophthalmic & vision research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Donald C HoodDepartment of Psychology, Columbia University.
Carlos G De MoraesBernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY.

Funding

Tests of Models of Retinal/Optic Nerve Diseases&AdaptionR01EY002115 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HOOD, DONALD C. · 1985 to 2018
$7.4M
Structural and Functional Progression of Glaucomatous Damage to the MaculaR01EY025253 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DE MORAES, CARLOS GUSTAVO · 2015 to 2017
$1.2M
NEI NIH HHS R01 EY002115NEI NIH HHS R01 EY025253
6 · The paper itself

Abstract

We pose 4 questions for the clinician diagnosing and monitoring glaucoma, and supply evidence-based answers. The first question is: "When do you perform a 10-2 (2-degree grid) visual field (VF) test?" We argue the best answer is: anyone you would do, or have done, a 24-2 (6-degree grid) VF on should have both a 24-2 and a 10-2 VF within the first 2 visits. Second, "When do you perform an optical coherence tomography (OCT) scan of the macula?" We argue that, if you are performing an OCT test, then it should include both the macula and disc, either as a single scan or as 2 scans, one centered on the macula and the other on the disc. Third, "How do you know if the VF and OCT tests agree?" The poor answer is, "I use summary statistics such as 24-2 mean deviation and global or quadrant average of retinal nerve fiber layer (RNFL) thickness." It is much better to topographically compare abnormal regions on the OCT to abnormal regions on the VF. Finally, the fourth question is: "When do you look at OCT images?" We argue that, at a minimum, the clinician should be directly examining an image of the circumpapillary RNFL, and this image should be sufficiently large and with sufficient resolution so that local damage can be seen, and the segmentation evaluated.

Indexed as

FemaleGlaucomaHumansMacula LuteaMaleMiddle AgedNerve FibersOptic Nerve DiseasesReproducibility of ResultsRetinal Ganglion CellsTomography, Optical CoherenceVision DisordersVisual FieldsVisual Field Tests

Identifiers

PMID29917000
PMCPMC6076318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.